Prot #NU 16G03: An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date10/18/165/28/24

Funding

  • Merck Sharp & Dohme Corporation ((OE) Prot #NU 16G03)